Reduced Susceptibility to Praziquantel among Naturally Occurring Kenyan Isolates of Schistosoma mansoni
Tóm tắt
Từ khóa
Tài liệu tham khảo
P Steinmann, 2006, Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk., Lancet Infect Dis, 6, 411, 10.1016/S1473-3099(06)70521-7
A Fenwick, 2003, Drugs for the control of parasitic diseases: current status and development in schistosomiasis., Trends Parasitol, 19, 509, 10.1016/j.pt.2003.09.005
DW Crompton, 1999, How much human helminthiasis is there in the world?, J Parasitol, 85, 397, 10.2307/3285768
P Hagan, 2004, Schistosomiasis control: keep taking the tablets., Trends Parasitol, 20, 92, 10.1016/j.pt.2003.11.010
A Fenwick, 2006, Schistosomiasis: challenges for control, treatment and drug resistance., Curr Opin Infect Dis, 19, 577, 10.1097/01.qco.0000247591.13671.6a
SA Satayathum, 2006, Factors affecting infection or reinfection with <italic>Schistosoma haematobium</italic> in coastal Kenya: survival analysis during a nine-year, school-based treatment program., Am J Trop Med Hyg, 75, 83, 10.4269/ajtmh.2006.75.83
A Danso-Appiah, 2002, Interpreting low praziquantel cure rates of <italic>Schistosoma mansoni</italic> infections in Senegal., Trends Parasitol, 18, 125, 10.1016/S1471-4922(01)02209-7
B Gryseels, 1987, Field trials of praziquantel and oxamniquine for the treatment of schistosomiasis mansoni in Burundi., Trans R Soc Trop Med Hyg, 81, 641, 10.1016/0035-9203(87)90439-1
P Magnussen, 2003, Treatment and re-treatment strategies for schistosomiasis control in different epidemiological settings: a review of 10 years' experiences., Acta Trop, 86, 243, 10.1016/S0001-706X(03)00045-7
PG Fallon, 1994, Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in <italic>Schistosoma mansoni</italic> in mice is drug specific., Am J Trop Med Hyg, 51, 83, 10.4269/ajtmh.1994.51.83
M Ismail, 1996, Characterization of isolates of <italic>Schistosoma mansoni</italic> from Egyptian villagers that tolerate high doses of praziquantel., Am J Trop Med Hyg, 55, 214, 10.4269/ajtmh.1996.55.214
M Ismail, 1999, Resistance to praziquantel: direct evidence from <italic>Schistosoma mansoni</italic> isolated from Egyptian villagers., Am J Trop Med Hyg, 60, 932, 10.4269/ajtmh.1999.60.932
B Gryseels, 1994, Epidemiology, immunology and chemotherapy of <italic>Schistosoma mansoni</italic> infections in a recently exposed community in Senegal., Trop Geogr Med, 46, 209
FF Stelma, 1997, Oxamniquine cures <italic>Schistosoma mansoni</italic> infection in a focus in which cure rates with praziquantel are unusually low., J Infect Dis, 176, 304, 10.1086/517273
B Gryseels, 2001, Are poor responses to praziquantel for the treatment of <italic>Schistosoma mansoni</italic> infections in Senegal due to resistance? An overview of the evidence., Trop Med Int Health, 6, 864, 10.1046/j.1365-3156.2001.00811.x
D Cioli, 2004, Determination of ED50 values for praziquantel in praziquantel-resistant and–susceptible <italic>Schistosoma mansoni</italic> isolates., Int J Parasitol, 34, 979, 10.1016/j.ijpara.2004.05.001
D Alonso, 2006, Failure of standard treatment with praziquantel in two returned travelers with <italic>Schistosoma haematobium</italic> infection., Am J Trop Med Hyg, 74, 342, 10.4269/ajtmh.2006.74.342
CH King, 2000, Evidence against rapid emergence of praziquantel resistance in <italic>Schistosoma haematobium</italic>, Kenya., Emerg Infect Dis, 6, 585, 10.3201/eid0606.000606
S Botros, 2005, Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt., Int J Parasitol, 35, 787, 10.1016/j.ijpara.2005.02.005
MJ Doenhoff, 1998, Is Schistosomicidal Chemotherapy Sub-curative? Implications for Drug Resistance., Parasitol Today, 14, 434, 10.1016/S0169-4758(98)01315-5
ML Steinauer, Genetic structure of <italic>Schistosoma mansoni</italic> in western Kenya: the effects of geography and host sharing., Int J Parasitol. E-Pub ahead of print
JA Morgan, 2005, Origin and diversification of the human parasite <italic>Schistosoma mansoni</italic>., Mol Ecol, 14, 3889, 10.1111/j.1365-294X.2005.02709.x
L Pica-Mattoccia, 2004, Sex- and stage-related sensitivity of <italic>Schistosoma mansoni</italic> to <italic>in vivo</italic> and <italic>in vitro</italic> praziquantel treatment., Int J Parasitol, 34, 527, 10.1016/j.ijpara.2003.12.003
S William, 2004, Validation of sensitivity to praziquantel using <italic>Schistosoma mansoni</italic> worm muscle tension and Ca2+-uptake as possible <italic>in vitro</italic> correlates to <italic>in vivo</italic> ED50 determination., Int J Parasitol, 34, 971, 10.1016/j.ijpara.2004.04.005
YS Liang, 2001, <italic>In vitro</italic> responses of praziquantel-resistant and -susceptible <italic>Schistosoma mansoni</italic> to praziquantel., Int J Parasitol, 31, 1227, 10.1016/S0020-7519(01)00246-6
DM Karanja, 1998, Studies on schistosomiasis in western Kenya: II. Efficacy of praziquantel for treatment of schistosomiasis in persons coinfected with human immunodeficiency virus-1., Am J Trop Med Hyg, 59, 307, 10.4269/ajtmh.1998.59.307
CL Black, 2009, Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya., Trop Med Int Health, 14, 450, 10.1111/j.1365-3156.2009.02234.x
PN Mwinzi, 2001, Cellular immune responses of schistosomiasis patients are altered by human immunodeficiency virus type 1 coinfection., J Infect Dis, 184, 488, 10.1086/322783
DM Karanja, 2002, Resistance to reinfection with <italic>Schistosoma mansoni</italic> in occupationally exposed adults and effect of HIV-1 co-infection on susceptibility to schistosomiasis: a longitudinal study., Lancet, 360, 592, 10.1016/S0140-6736(02)09781-7
ML Steinauer, 2008, Interactions between natural populations of human and rodent schistosomes in the Lake Victoria region of Kenya: a molecular epidemiological approach., PLoS Negl Trop Dis, 2(4), 1
R Gönnert, 1977, Praziquantel, a new board-spectrum antischistosomal agent., Z Parasitenkd, 52, 129, 10.1007/BF00389899
MG Radke, 1971, <italic>Schistosoma mansoni</italic>: mouse mortality test system for mass screening for prophylactic drugs., Exp Parasitol, 30, 1, 10.1016/0014-4894(71)90063-4
AD Aragon, 2009, Towards an understanding of the mechanism of action of praziquantel., Mol Biochem Parasitol, 164, 57, 10.1016/j.molbiopara.2008.11.007
PG Fallon, 1995, Short report: diminished susceptibility to praziquantel in a Senegal isolate of <italic>Schistosoma mansoni</italic>., Am J Trop Med Hyg, 53, 61, 10.4269/ajtmh.1995.53.61
R Pax, 1978, A benzodiazepine derivative and praziquantel: effects on musculature of <italic>Schistosoma mansoni</italic> and <italic>Schistosoma japonicum</italic>., Naunyn Schmiedebergs Arch Pharmacol, 304, 309, 10.1007/BF00507974
PJ Brindley, 1991, Characterization of a programmed alteration in an 18S ribosomal gene that accompatnies the experimental induction of drug resistance in <italic>Schistosoma mansoni</italic>., Proc Natl Acad Sci U S A, 88, 7754, 10.1073/pnas.88.17.7754
Y Carmeli, 2008, Strategies for managing today's infections., Clin Micro Infection, 14, 22, 10.1111/j.1469-0691.2008.01957.x
CR Caffrey, 2008, Recent initiatives and strategies to developing new drugs for tropical parasitic diseases., Exp Opin Drug Discovery, 3, 173, 10.1517/17460441.3.2.173
MM Hassan, 1992, Circulating schistosomal antigen in diagnosis and assessment of cure in individuals infected with <italic>Schistosoma mansoni</italic>., Am J Trop Med Hyg, 46, 737, 10.4269/ajtmh.1992.46.737
AN Sabra, 2008, Response of <italic>Schistosoma mansoni</italic> isolates having different drug sensitivity to praziquantel over several life cycle passages with and without therapeutic pressure., J Parasitol, 94, 537, 10.1645/GE-1297.1
F Depardieu, 2007, Modes and modulation of antibiotic resistance gene expression., Clin Microbiol Rev, 20, 79, 10.1128/CMR.00015-06
JA Van Wyk, 2001, Refugia: Overlooked as perhaps the most potent factor concerning the development of anthelmintic resistance., Onderstepoort J Vet Res, 68, 55